Clinical trials: Kidney Transplant Rejection
Kidney Transplantation, Kidney Disease
Urine Testing to Detect Kidney Transplant Rejection
The purpose of this study is to determine if analysis of urine samples for specific markers can predict transplant rejection in people who have received kidney transplants.
- Conditions
- Kidney Transplantation, Kidney Disease, Kidney Failure, Chronic
- Trial name
- NCT00337220
- Where
- 5 sites in United States
- Volunteers
- 492 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Diseases, Kidney Transplant
TreaT-Assay: the New Frontier for the Diagnosis of Acute Rejection in Kidney Transplantation
Kidney transplantation is the standard therapy for end-stage renal disease. Acute rejection (AR) or chronic rejection along with reactive donor immunity, which counteracts organ acceptance, are among the greatest medical…
- Conditions
- Kidney Diseases, Kidney Transplant, Kidney Disease, End-Stage
- Trial name
- NCT06801262
- Where
- Italy
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Renal Transplant Rejection, Immune Repertoire
ALLoreactive T-Cell receptOr RePertoire in kidnEy tranSplantation
In this study, the investigators will establish a workflow to generate unique patterns of the donor-reactive T cell repertoire using mixed lymphocyte reactions to select alloreactive T cell clones prior to transplantation Tissue…
- Conditions
- Renal Transplant Rejection, Immune Repertoire, Transplant; Complication, Rejection, Alloreactivity
- Trial name
- ALL-T-COPIES (NCT03422224)
- Testing
- Mixed lymphocyte reaction
- Where
- Austria
- Volunteers
- 50 people
- Sponsor
- Medical University of Vienna
Antibody-mediated Rejection, Kidney Tranplant
The Safety and Efficacy of CD38 Monoclonal Antibody Monotherapy for CaAMR in Renal Transplantation
Renal transplantation is the best choice for the treatment of end-stage renal disease, but the long-term survival of the graft is still remains a challenge.
- Trial name
- NCT05913596
- Testing
- Daratumumab
- Where
- China
- Volunteers
- 15 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Disorder Related to Renal Transplantation
The Effects of Spironolactone on Calcineurin Inhibitor Induced Nephrotoxicity
The purpose of this study is to assess whether the diuretic drug spironolactone can prevent chronic damage to transplanted kidneys caused by the medication that prevents rejection.
- Trial name
- SPIREN (NCT01602861)
- Testing
- Spironolactone
- Where
- Denmark
- Volunteers
- 188 people
- Sponsor
- Odense University Hospital
Kidney Transplantation
Rituximab for Prevention of Rejection After Renal Transplantation
Our standard immunosuppressive treatment after renal transplantation is a combination of tacrolimus, mycophenolate mofetil, and prednisolone.
- Trial name
- NCT00565331
- Testing
- Rituximab
- Where
- Netherlands
- Volunteers
- 280 people
- Sponsor
- Radboud University Medical Center
Posttransplant Diabetes Mellitus, Acute Graft Rejection
Silymarin's Advantage on Graft Effectiveness
The study examines the impact of silymarin supplementation during the early post-transplant period, administering 900 g daily for 30 days under standard treatment.
- Conditions
- Posttransplant Diabetes Mellitus, Acute Graft Rejection, Biopsy Proven Acute Rejection, Antibody Mediated Rejection of Kidney Transplant
- Trial name
- SAGE (NCT06801886)
- Testing
- Silymarine supplementation
- Where
- Slovakia
- Volunteers
- 130 people
- Sponsor
- University Hospital, Martin
Kidney Transplantation
Iguratimod in Kidney Transplant Recipients
The objective of the study is to evaluate the effect of iguratimod concomitant with conventional immunosuppressive drugs on preventing antibody-induced rejection in HLA Highly mismatched Kidney Transplant recipients.
- Trial name
- NCT02839941
- Testing
- Iguratimod, Mycophenolate mofetil, Tacrolimus
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Humoral Rejection in Kidney Transplantation
Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation
Assessing the impact of J12 curative treatment with rituximab (375 mg / m² on J5) based on a composite "TREATMENT FAILURE"
- Trial name
- RITUX-ERAH (NCT01350882)
- Testing
- MabThera, Physiological serum : sodium chloride, sodium citrate
- Where
- 30 sites in France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Tours
Acute Rejection, Renal Transplantation
Campath, Rituximab, and Myfortic With Short-Course Calcineurin Inhibitor Therapy in Renal Transplanation
The hypothesis of this study is that lymphocyte depletion by Campath-1H and rituximab will obviate the need for long-term calcineurin inhibitors in renal transplantation.
- Trial name
- NCT00579592
- Testing
- Campath-1H, rituximab, myfortic
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Wisconsin, Madison
Kidney Transplantation, Kidney Failure, Chronic
Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection
In small initial studies, combined kidney and bone marrow transplants from the same donor have permitted some individuals to stop taking anti-rejection medicines without rejecting their transplant.
- Trial name
- NCT00801632
- Testing
- Kidney Transplantation, Bone marrow transplantation, MEDI-507
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Transplant;Failure,Kidney, Transplant; Failure, Pancreas
Eliminating the Need for Pancreas Biopsy Using Peripheral Blood Cell-free DNA
Donor-derived cell-free DNA (dd-cfDNA) has shown promise as an early marker for cellular injury caused by rejection. dd-cfDNA changes may also indicate other injuries that lead to progressive decline in transplant organ function…
- Conditions
- Transplant;Failure,Kidney, Transplant; Failure, Pancreas, Rejection Acute Renal, Rejection Acute Pancreas
- Trial name
- PancDX (NCT04166149)
- Testing
- dd-cfDNA Blood Test
- Where
- 3 sites in United States
- Volunteers
- 140 people
- Sponsor
- University of Maryland, Baltimore
Kidney Transplant
Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation
The purpose of this study is to try to determine if the drug eculizumab can help prevent antibody-mediated rejection in patients undergoing a kidney transplant from a living donor with a different blood type than their own.
- Trial name
- ABOi (NCT01095887)
- Testing
- Eculizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Mayo Clinic
Kidney Transplantation, Kidney Allograft Biopsy
Study of Alloimmune Response in Humoral Rejection After Kidney Transplantation
We will study a prospective cohort including all kidney transplant recipients undergoing kidney graft biopsy in one kidney transplantation center, for a duration of 5 years.
- Conditions
- Kidney Transplantation, Kidney Allograft Biopsy, Humoral Rejection, Microvascular Inflammation
- Trial name
- RECITE (NCT05890430)
- Testing
- Blood draw, Urine draw
- Volunteers
- 570 people
- Sponsor
- University Hospital, Strasbourg, France
Acute Graft Rejection, Chronic Allograft Nephropathy
Study Cyclosporine (CsA) Versus Tacrolimus (Tacro) After Campath Induction in Kidney Transplantation
After alemtuzumab induction, followed with kidney transplantation, patients will be randomly assigned to receive either tacrolimus or cyclosporine microemulsion in combination with mycophenolates.
- Conditions
- Acute Graft Rejection, Chronic Allograft Nephropathy, Polyomavirus-related Transplant Nephropathy
- Trial name
- RSCS-Campath (NCT01346397)
- Testing
- cyclosporine or tacrolimus
- Where
- Russia
- Volunteers
- 170 people
- Sponsor
- Russian Academy of Medical Sciences